Worth Venture Partners’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Worth Venture Partners’s Portfolio VCNX Stock Details VCNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-46,720	Closed	-$435K	–	128
2023 Q4	$435K	Sell	46,720 -4,534	-9%	-$53.6K	0.24%	77
2023 Q3	$811K	Buy	51,254 +50,593	+7,654%	+$2.57M	0.48%	58
2023 Q2	$49.4K	Hold	661	–	–	0.03%	142
2023 Q1	$55.4K	Sell	661 -1,757	-73%	-$193K	0.03%	155
2022 Q4	$335K	Hold	2,418	–	–	0.2%	92
2022 Q3	$251K	Hold	2,418	–	–	0.15%	101
2022 Q2	$564K	Buy	2,418 +2,100	+660%	+$537K	0.33%	75
2022 Q1	$88K	Buy	+318	New	+$87.9K	0.04%	122

Other funds holding VCNX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Tacita Capital Toronto, Ontario, Canada $184M AUM 26.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Worth Venture Partners's VCNX Position: Q1 2024 in Review

Worth Venture Partners sold out of Vaccinex, Inc. Common Stock (VCNX) in Q1 2024, closing a stake of 46,720 shares — an estimated $435K sold.

Worth Venture Partners first reported a position in VCNX in Q1 2022 and held it in 8 quarters. The position peaked at $811K in Q3 2023. 12 funds tracked by Wall St. Rank hold VCNX as of Q1 2024.

Worth Venture Partners reported no remaining Vaccinex, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Worth Venture Partners sold 46,720 Vaccinex, Inc. Common Stock shares in Q1 2024, an estimated $435K.
Worth Venture Partners first reported a position in Vaccinex, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
Worth Venture Partners's Vaccinex, Inc. Common Stock position peaked at $811K in Q3 2023.
12 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q1 2024.

Based on Worth Venture Partners's 13F filing for Q1 2024, filed 13 May 2024.